High-dose intravenous immunoglobulin therapy in multifocal motor neuropathy

Eduardo Nobile-Orazio, N. Meucci, S. Barbieri, M. Carpo, G. Scarlato

Research output: Contribution to journalArticle

190 Citations (Scopus)

Abstract

We treated five consecutive patients with multifocal motor neuropathy (MMN) with high-dose intravenous immunoglobulin (IVIg). Four patients had increased levels of anti-asialo-GM1 IgM and two of anti-GM1 IgM as well; one patient had no reactivity. We treated them twice with 0.4 g/kg IVIg for 5 consecutive days at a 2-month interval, followed by maintenance infusions up to 6 to 12 months. All patients with high anti-asialo-GM1 had a consistent clinical improvement starting 3 to 10 days after the first IVIg course; in one patient, recovery was complete and persistent for 12 months without additional treatment, while in three patients, improvement only lasted 20 to 30 days. There was a similar improvement in these patients after the second course of IVIg which was maintained by periodic 2-day IVIg infusions. Clinical improvement in these patients was associated with a reduction of conduction block in most, but not all, motor nerves, while antibody titers were not consistently modified by treatment. There was no clinical or electrophysiologic improvement in the patient without antiglycolipid activity after 6 months of IVIg. IVIg may be a safe and effective therapy for MMN.

Original languageEnglish
Pages (from-to)537-544
Number of pages8
JournalNeurology
Volume43
Issue number3
Publication statusPublished - 1993

Fingerprint

Passive Immunization
Intravenous Immunoglobulins
Therapy
Dose
Intravenous Infusions
Immunoglobulin M
Therapeutics
Maintenance
Antibodies

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology
  • Neuroscience(all)

Cite this

High-dose intravenous immunoglobulin therapy in multifocal motor neuropathy. / Nobile-Orazio, Eduardo; Meucci, N.; Barbieri, S.; Carpo, M.; Scarlato, G.

In: Neurology, Vol. 43, No. 3, 1993, p. 537-544.

Research output: Contribution to journalArticle

Nobile-Orazio, E, Meucci, N, Barbieri, S, Carpo, M & Scarlato, G 1993, 'High-dose intravenous immunoglobulin therapy in multifocal motor neuropathy', Neurology, vol. 43, no. 3, pp. 537-544.
Nobile-Orazio, Eduardo ; Meucci, N. ; Barbieri, S. ; Carpo, M. ; Scarlato, G. / High-dose intravenous immunoglobulin therapy in multifocal motor neuropathy. In: Neurology. 1993 ; Vol. 43, No. 3. pp. 537-544.
@article{0870aae0d2d14c859b98e51567d1f702,
title = "High-dose intravenous immunoglobulin therapy in multifocal motor neuropathy",
abstract = "We treated five consecutive patients with multifocal motor neuropathy (MMN) with high-dose intravenous immunoglobulin (IVIg). Four patients had increased levels of anti-asialo-GM1 IgM and two of anti-GM1 IgM as well; one patient had no reactivity. We treated them twice with 0.4 g/kg IVIg for 5 consecutive days at a 2-month interval, followed by maintenance infusions up to 6 to 12 months. All patients with high anti-asialo-GM1 had a consistent clinical improvement starting 3 to 10 days after the first IVIg course; in one patient, recovery was complete and persistent for 12 months without additional treatment, while in three patients, improvement only lasted 20 to 30 days. There was a similar improvement in these patients after the second course of IVIg which was maintained by periodic 2-day IVIg infusions. Clinical improvement in these patients was associated with a reduction of conduction block in most, but not all, motor nerves, while antibody titers were not consistently modified by treatment. There was no clinical or electrophysiologic improvement in the patient without antiglycolipid activity after 6 months of IVIg. IVIg may be a safe and effective therapy for MMN.",
author = "Eduardo Nobile-Orazio and N. Meucci and S. Barbieri and M. Carpo and G. Scarlato",
year = "1993",
language = "English",
volume = "43",
pages = "537--544",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - High-dose intravenous immunoglobulin therapy in multifocal motor neuropathy

AU - Nobile-Orazio, Eduardo

AU - Meucci, N.

AU - Barbieri, S.

AU - Carpo, M.

AU - Scarlato, G.

PY - 1993

Y1 - 1993

N2 - We treated five consecutive patients with multifocal motor neuropathy (MMN) with high-dose intravenous immunoglobulin (IVIg). Four patients had increased levels of anti-asialo-GM1 IgM and two of anti-GM1 IgM as well; one patient had no reactivity. We treated them twice with 0.4 g/kg IVIg for 5 consecutive days at a 2-month interval, followed by maintenance infusions up to 6 to 12 months. All patients with high anti-asialo-GM1 had a consistent clinical improvement starting 3 to 10 days after the first IVIg course; in one patient, recovery was complete and persistent for 12 months without additional treatment, while in three patients, improvement only lasted 20 to 30 days. There was a similar improvement in these patients after the second course of IVIg which was maintained by periodic 2-day IVIg infusions. Clinical improvement in these patients was associated with a reduction of conduction block in most, but not all, motor nerves, while antibody titers were not consistently modified by treatment. There was no clinical or electrophysiologic improvement in the patient without antiglycolipid activity after 6 months of IVIg. IVIg may be a safe and effective therapy for MMN.

AB - We treated five consecutive patients with multifocal motor neuropathy (MMN) with high-dose intravenous immunoglobulin (IVIg). Four patients had increased levels of anti-asialo-GM1 IgM and two of anti-GM1 IgM as well; one patient had no reactivity. We treated them twice with 0.4 g/kg IVIg for 5 consecutive days at a 2-month interval, followed by maintenance infusions up to 6 to 12 months. All patients with high anti-asialo-GM1 had a consistent clinical improvement starting 3 to 10 days after the first IVIg course; in one patient, recovery was complete and persistent for 12 months without additional treatment, while in three patients, improvement only lasted 20 to 30 days. There was a similar improvement in these patients after the second course of IVIg which was maintained by periodic 2-day IVIg infusions. Clinical improvement in these patients was associated with a reduction of conduction block in most, but not all, motor nerves, while antibody titers were not consistently modified by treatment. There was no clinical or electrophysiologic improvement in the patient without antiglycolipid activity after 6 months of IVIg. IVIg may be a safe and effective therapy for MMN.

UR - http://www.scopus.com/inward/record.url?scp=0027401494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027401494&partnerID=8YFLogxK

M3 - Article

VL - 43

SP - 537

EP - 544

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 3

ER -